**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 47519**

**Manuscript type: REVIEW**

**Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma**

Akateh C *et al*. Management strategies for HCC

Clifford Akateh, Sylvester M Black, Lanla Conteh, Eric D Miller, Anne Noonan, Eric Elliott, Timothy M Pawlik, Allan Tsung, Jordan M Cloyd

**Clifford Akateh,** Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Sylvester M Black,** Division of Transplant Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Lanla Conteh,** Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Eric D Miller,** Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Anne Noonan,** Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Eric Elliott,** Division of Diagnostic Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**Timothy M Pawlik, Allan Tsung, Jordan M Cloyd,** Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**ORCID number:** Clifford Akateh (0000-0003-2936-9779); Sylvester M Black (0000-0003-3595-1159); Lanla Conteh (0000-0002-4372-993X); Eric D Miller (0000-0002-4748-153X); Anne Noonan (0000-0001-8083-8492); Eric Elliott (0000-0001-7885-7686); Timothy M Pawlik (0000-0002-4828-8096); Allan Tsung (0000-0002-3916-8965); Jordan M Cloyd (0000-0002-2373-8433).

**Author contributions:** Akateh C and Cloyd JM contributed to the study design, manuscript writing and critical revision. Black SM, Conteh L, Miller ED, Noonan A, Elliot E, Pawlik TM and Tsung A contributed to the manuscript writing and critical revision.

**Conflict-of-interest statement:** The authors have no conflicts of interest to disclose.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Jordan M Cloyd, MD, Assistant Professor,** Division of Surgical Oncology, The Ohio State Wexner Medical Center, 410 W 10th Ave, N-907, Columbus, OH 43210, United States. jordan.cloyd@osumc.edu

**Telephone:** +1-614-2935365

**Fax:** +1-614-3660003

**Received:** March 19, 2019

**Peer-review started:** March 19, 2019

**First decision:** April 30, 2019

**Revised:** June 13, 2019

**Accepted:** June 22, 2019

**Article in press:**

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or *de novo* cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant therapies and discuss opportunities for future clinical and translational research.

**Key words:** Hepatocellular carcinoma; Neoadjuvant therapy; Adjuvant therapy; Neoplasm recurrence; Hepatectomy; Liver cirrhosis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Liver resection is an important curative-intent treatment option for patients with hepatocellular carcinoma (HCC). However, advanced disease, underlying chronic liver disease and/or cirrhosis, limits the proportion of patients who are surgical candidates. Recurrent disease is unfortunately common even after undergoing resection. As such, the benefits of neoadjuvant and adjuvant treatment strategies aimed at improving resectability and decreasing recurrence rates are of great interest. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC.

Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, representing the third most common malignancy in men and seventh in women[1,2]. In the United States, there was an estimated 42220 new cases of HCC and an estimated 30200 HCC-related deaths in 2018[3]. Unfortunately, the incidence of HCC is rising and, unlike most other cancers, this increased incidence affects all major demographic groups and populations[4,5]. This increase is particularly higher in men, who have a four-fold increased risk of developing HCC[6,7]. The vast majority of HCC occurs in the setting of chronic liver disease (CLD) with or without cirrhosis most often secondary to chronic hepatitis B (HBV) and hepatitis C (HCV) infections, although there is also a rising incidence of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) related cirrhosis[8-11]. Other major causes include alcoholic cirrhosis, as well as diabetes, hemochromatosis, Alpha 1-antitrypsin deficiency, Wilson’s disease, hemophilia, and Aflatoxin[12-15]. Thus, patients with HCC have two simultaneous challenges: the malignancy itself and the underlying liver disease which can both complicate treatment and predispose to the development of recurrent or *de novo* cancers.

While numerous systemic and locoregional treatments exist for patients with HCC, curative-intent options mainly include liver transplantation (LT), surgical resection, and ablative therapies. Although LT is appealing in that it treats both the cancer and the underlying CLD, a major challenge is the deficiency of available organs in the United States and around the world. Furthermore, many patients with relatively preserved liver function (*e.g.*, chronic HBV) or those outside Milan criteria (*e.g.*, large solitary tumor or macrovascular invasion) are not eligible for LT. Ablation is a reasonable treatment option, but its outcomes are optimized in patients with small tumors[16]. Therefore, surgical resection remains an important primary treatment option for HCC which, in appropriately selected patients and when performed by experienced surgical teams, is associated with excellent results. Unfortunately, a minority of patients are surgical candidates due to either advanced disease or inadequate liver function to safely undergo hepatectomy. Furthermore, recurrence rates among those patients who are able to undergo surgical resection is relatively common[17].

The last few decades have led to significant advances in both the treatment of viral hepatitis as well as systemic and locoregional treatment options for HCC. Whether these strategies can be used prior to or following surgical resection in order to increase the number of patients who are surgical candidates or to reduce the risk of tumor recurrence following resection remains poorly understood. Indeed, relatively little research has been conducted on the optimal multimodality therapy for patients with surgically resected HCC. In this review paper, we sought to evaluate the available literature on neoadjuvant and adjuvant treatment strategies for patients with resectable HCC.

**NEOADJUVANT STRATEGIES FOR HCC**

While neoadjuvant therapies are commonly used for patients with other solid-organ malignancies in order to downstage advanced disease, ensure appropriate patient selection, and assess tumor response to treatment prior to resection, the role of neoadjuvant therapies in the management of HCC is less well defined. Indeed, relatively little research exists to support the concept of neoadjuvant therapy, and current guidelines do not recommend this strategy for patients with otherwise potentially resectable cancers. On the other hand, the unique characteristics of HCC, including its relatively aggressive biology, frequent diagnosis at late stages, and the need to preserve normal liver function at the time of surgery given underlying CLD, suggest a neoadjuvant approach may be appropriate.

***Transarterial chemoembolization***

Transarterial chemoembolization (TACE) combines transarterial embolization (TAE) with chemotherapy infusion. Unlike normal liver tissue, which derives most of its blood supply from the portal venous system, HCCs derive most of their blood supply from the hepatic artery system. As such, embolization of the arterial system results in ischemia and tissue necrosis[18] while allowing for the concentrated delivery of chemotherapy agents. Embolization also prevents the chemotherapeutic agent from being washed out, allowing for a longer duration of action.

TACE was originally developed for management of advanced unresectable disease, but its role in the neoadjuvant treatment of potentially resectable disease has also been explored. One of the earliest experiences with neoadjuvant TACE was reported by Monden *et al*[19]. The investigators compared 71 patients treated preoperatively with TACE to 21 patients resected without TACE. Although they did not find any differences in survival, histopathologic review demonstrated that tumors from most of the patients who underwent TACE procedure were necrotized. In 2000, Zhang *et al*[20] conducted a retrospective review of 1457 patients who underwent hepatic resection for HCC at their hospital, including 120 patients treated preoperatively with TACE. Compared to those resected without TACE, patients who underwent preoperative TACE had significantly improved 5‐year disease‐free survival (DFS). In addition, patients who had more than two preoperative TACE treatments had longer recurrence-free survival (RFS) compared to patients who only had one session. However, a different institutional study from China comparing 183 neoadjuvant TACE to 405 resection-only cases found no difference in 1-, 3-, and 5-year overall survival (OS). Instead, repeated TACE use was associated with significantly higher hospital cost[21]. However, results from a meta-analysis by Qi *et al*[22] provided some insight into the discordant results. In their analysis of 32 randomized and non-randomized studies evaluating preoperative TACE to resection-only, they found that preoperative TACE did not improve DFS or OS. However, a subgroup analysis of the results suggested that the outcomes of neoadjuvant TACE followed by resection were influenced by the response to TACE. When patients had complete tumor necrosis following TACE, preoperative TACE had significantly better DFS and OS compared to resection alone. However, when patients had incomplete or no tumor necrosis, the OS did not differ between the two groups.

In addition to its prognostic impact, investigators have shown interest in the ability to downstage previously unresectable patients with neoadjuvant TACE[23-25]. Zhang *et al*[26] reviewed the results from 831 patients over 10 years treated with TACE. Of these, 82 patients were successfully downstaged, and 43 underwent salvage surgery. Compared to those who refused a salvage resection, those who underwent resection had a longer median OS (49 mo *vs* 31 mo, *P* = 0.027). However, there was no difference in survival based on the receipt of surgery among patients who experienced a complete response (50 mo *vs* 54 mo, *P* = 0.699) compared to patients with only a partial response (49 mo *vs* 24 mo, *P* < 0.001). These findings suggest a critical role for resection following downstaging with TACE in patients with a partial response.

Preoperative TACE has also been investigated in the management of recurrent but resectable disease. Tao *et al*[27] showed that for patients with recurrent but resectable disease, preoperative TACE did not improve survival. On the other hand, it was associated with increased preoperative time and increased blood loss. For patients undergoing extended resections who require preoperative portal vein embolization (PVE) to stimulate compensatory hypertrophy of the future liver remnant[28], preoperative TACE has been investigated as a means of controlling tumor growth. Some speculate that, in the absence of TACE, PVE can result in increased ipsilateral hepatic artery flow, and as such, increased tumor growth. Indeed, some studies have demonstrated improved RFS and OS among patients undergoing TACE+PVE compared to PVE alone[29,30].

In conclusion, the role of TACE in neoadjuvant therapy continues to evolve. While some studies suggest an opportunity to downstage some patients to resection as well as improved long-term outcomes among patients who develop a radiographic response, these therapies currently apply to a minority of patients with HCC, and there is insufficient evidence to predict which patients will respond. Therefore, while TACE is commonly used as a bridging therapy prior to LT[31], its role in the neoadjuvant setting prior to resection remains unclear and is not routinely recommended.

***Transarterial radioembolization***

Transarterial radioembolization (TARE) is increasingly being performed as an alternative to TACE for patients with HCC. TARE uses 90Yttrium (Y-90) loaded microspheres and delivers these radioactive microspheres via arterial cannulation of the feeding vessel[32]. While there is no overwhelming evidence to suggest superiority over TACE, TARE offers several advantages, including a lower side effect profile (*i.e.*, less post-embolization syndrome)[33]. In addition, for potentially resectable patients, TARE leads to hypertrophy of the contralateral future liver remnant (FLR) in addition to its cytotoxic effects on the tumor[34-36]. This characteristic of TARE has given rise to the concept of radiation lobectomy (RL), a technique which induces hypertrophy to equal or higher levels than PVE[34]. In 2013, Vouche *et al*[35] reported on 67 patients with HCC subjected to Y-90 radioembolization. 37% of the patients had a greater than 35% increase in the FLR, of whom 3 patients went on to have a successful right hepatectomy, and 6 were transplanted. In 2016, they reported on another group of 10 patients with HCC and insufficient or borderline FLR who underwent Y-90 RL prior to resection. Following RL, the median FLR increased from about 33% (pre-RL) to about 43% (post-RL). Additionally, they reported > 50% necrosis in greater than 92% of the resected tumors[37]. TARE has also been combined with PVE to successfully downstage patients for resection when additional FLR hypertrophy is required[38].

Another advantage of TARE is its application in patients with portal vein thrombosis. Patients with malignant lobar portal vein thrombosis are typically not considered candidates for TACE. Therefore, TARE offers an alternate and preferable approach in the neoadjuvant management of such patients. In a previously reported non-randomized trial comparing TARE to TACE, TARE resulted in a better response than TACE (61% *vs* 37% partial response) and resulted in more patients being downstaged from UNOS T3 to T2, which could be critical for patients awaiting transplantation[39]. So, while most guidelines do not recommend one modality over the other for downstaging[40-43], an expert consensus group recommend TARE over TACE as a bridging/downstaging therapy for patients with portal venous thrombosis[44]. Therefore, while further research is needed, including prospective clinical trials, neoadjuvant TARE with Y-90 may be appropriate for patients with advanced HCC who require downstaging for resection.

***Systemic therapy***

Until recently, there have been few effective systemic therapy options for patients with HCC. In 2007, the tyrosine kinase inhibitor (TKI) Sorafenib was approved for use in patients with Childs A cirrhosis and unresectable or metastatic HCC[45-47]. Sorafenib has activity against several tyrosine kinases including Raf, as well as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF)[48,49]. Despite its poor side effect profile and OS improvement of < 3 mo, it quickly gained favor given the lack of other systemic therapy options available until 2017. While interest in Sorafenib as a bridging therapy to transplant was abundant[50,51], it was not felt to be an effective downstaging agent to facilitate surgical resection given the minimal response rate observed. Nevertheless, interest in the use of Sorafenib as a neoadjuvant chemotherapeutic agent remained[52,53] but its use has largely been limited by toxicity[54-57].

Over the past several years, there has been an explosion of newer agents approved for use or currently in clinical trials for advanced or metastatic HCC. For example, other TKIs and VEGF inhibitors including Lenvatinib[58], cabozantinib[59], regorafenib[60], and ramucirumab[61] have all demonstrated efficacy against HCC. However, none have been investigated in the neoadjuvant setting. Some of the most exciting progress has been made in immunotherapy. Nivolumab[62,63], pembrolizumab[64], tremelimumab[65], atezolizumab[66] and chimeric antigen receptor (CAR) T cells[67] have all been investigated or are under investigation for management of advanced HCC. Investigations of these immunotherapeutic agents in the neoadjuvant setting are ongoing at this time[68-70].

***Anti-viral therapy***

Among patients with HBV or HCV related HCC, a primary contributor to late recurrence is the *de novo* formation of new tumors related to underlying chronic viral hepatitis[71,72]. Therefore, antiviral therapy prior to resection of HCC should be considered as part of the multidisciplinary treatment of these patients. Indeed, preoperative antiviral therapy has been associated with lower vascular invasion, decreased recurrence, decreased morbidity and faster recovery of liver function in HBV-related HCC[73,74]. On the other hand, antiviral therapy has been more commonly used in the adjuvant setting, which will be described later in this review.

**ADJUVANT STRATEGIES FOR HCC**

While neoadjuvant strategies are often employed to facilitate downstaging of unresectable patients to potentially resectable candidates, immediate surgical resection remains the recommended treatment for patients with resectable tumors and appropriate liver function. However, recurrence is relatively common even among patients who undergo surgical resection. The purpose of adjuvant therapy, therefore, is to help decrease the incidence of HCC recurrence among those who undergo surgical resection. In general, recurrences following resection of HCC occur in two patterns: early and late. Early recurrences are typically thought to be related to negative prognostic factors (*e.g.*, margin positivity, vascular invasion, *etc.*) associated with the primary tumor while late recurrences are more likely related to underlying CLD and the development of *de novo* tumors. Adjuvant strategies that address both of these factors may be most effective.

***Antiviral therapy***

It has been long known that antiviral therapy following resection of HBV or HCV related HCC may improve outcomes[75-77]. In a 2013 matched control study by Hsu *et al*[78], researchers compared patients treated with pegylated interferon (PEG-IFN) plus ribavirin to a matched anti-viral naïve cohort and found significantly lower rates of HCC recurrence at 5 years in patients treated with interferon (52.1% *vs* 63.9%, *P* = 0.001). Lee *et al*[79], also, reported on a prospective trial of PEG-IFN following surgical resection, which included 93 patients (31 treated and 62 controls). They reported significantly lower recurrence rates at 1 and 2 years treated with interferon (7% *vs* 24% and 14% *vs* 34% respectively, *P* = 0.029). These findings were confirmed in a recent meta-analysis by Wu *et al*[80]. They reviewed 1 RCT and 4 cohort studies, totaling 1356 patients (345 PEG-IFN and 1011 control group) and reported a significant reduction in 3-year and 5-year recurrence rates with PEG-IFN treatment.

The development of direct-acting antiviral drugs (DAA) against HCV has increased the emphasis on adjuvant anti-viral therapy[81]. These interferon-free antivirals directly target the specific nonstructural proteins of the viral replication cycle, limiting replication and infectivity. The current classes include nonstructural proteins 3/4A (NS3/4A) protease inhibitors (PIs), NS5A complex inhibitors, NS5B nucleotide polymerase inhibitors (NPIs), and NS5B non-nucleotide polymerase inhibitors (NNPIs). Combining two or more of these agents has been associated with up to 90% HCV clearance[82]. While adequate surgical resection is necessary for disease control and to improve long-term survival, postoperative control of the chronic viral infection, and maintenance of a sustained virologic response remain critical in preventing recurrence and in ensuring a favorable outcome[83]. While an initial report by Reig et al[84] initially suggested an increase in recurrence rates among patients treated with DAA drugs, this findings was refuted by a large multicenter by Singal *et al*[85]. In this large retrospective analysis of 783 patients, 304 (38.3%) of whom received DAA agents, there was no significant difference in overall or early HCC recurrence. Indeed, there might be evidence to the contrary. Using propensity-score matching, Cabibbo *et al*[86] compared 102 patients with BCLC stage O or A HCC treated with DAA agents following curative resection or ablation to 102 matched controls. The researchers reported a significantly higher OS in the DAA group compared to the non-DAA group (HR = 0.39 *P* = 0.03). In addition, patients in the DAA group who achieved a sustained virologic response had a better OS, lower HCC recurrence rate and decreased incidence of hepatic decompensation. However, there was no difference in HCC recurrence between the DAA and non-DAA groups. As noted by Nault *et al*[87], despite these encouraging findings, more studies are needed to resolve this controversy.

The use of nucleoside analogs for adjuvant HBV treatment in HBV related HCC has also shown promise (Table 1). Indeed, multiple studies have demonstrated the efficacy of adjuvant antiviral therapy both for decreasing recurrence and for improving outcomes[72,88-91]. Huang *et al*[72] evaluated the role of nucleoside analogs on HCC recurrence in two separate RCTs. In 2015, the investigators randomized 200 patients with chronic HBV and no previous antiviral therapy, who had undergone an R0 resection of HCC to either postoperative antiviral therapy or no treatment. These authors reported a significant improvement in both OS and RFS. However, all patients in the study had high preoperative HBV-DNA levels (> 2000 IU/mL). More recently, they reported on a separate cohort, all with low (< 2000 IU/mL) preoperative viral levels. Following resection, patients were randomized to receive telbivudine daily or no treatment. The patients in the adjuvant antiviral treatment group had a significantly better 5-year OS (64% *vs* 44%) and RFS (52% *vs* 32%). Additionally, the treated patients had lower HBV reactivation rates[92]. Based on these studies, it may be appropriate to treat all patients with chronic HBV or HCV with antiviral therapy following resection, regardless of viral load. Current NCCN guidelines recommend consideration of such an approach[43,94].

***Systemic therapy***

Although systemic chemotherapy with is commonly used for patients with advanced and metastatic HCC, its use following curative resection is controversial. While early studies suggested that adjuvant systemic chemotherapy might be associated with decreased recurrence and prolonged RFS, other studies have found no benefit[95-97]. In contrast, some studies have shown that adjuvant chemotherapy may be associated with worse outcomes[96,98], which suggest that outcomes may be largely driven by the specific chemotherapeutic regimen and patient population. The STORM trial was a randomized phase 3, double-blind, placebo-controlled trial designed to evaluate the efficacy of sorafenib as adjuvant therapy in patients with resected HCC (although it included some patients with local ablation only). It included about 900 patients (450 in each arm) across 202 sites and in 28 countries who had undergone curative resection with evidence complete disease removal on radiography. After a median duration of about 12.5 months of treatment, there was no difference in RFS between the two groups. Instead, sorafenib treatment was associated with increased adverse effects, including four deaths[99].

The advent of immunotherapy and promising results of immunotherapeutic agents in advanced HCC has renewed interest in adjuvant systemic therapy following resection of HCC. One of the earliest uses of immunotherapy in the adjuvant setting was by Takayama *et al*[100]. From 1992-1995, the researchers randomized 150 patients to either lymphocyte infusions (termed adoptive immunotherapy) or no adjuvant treatment. Patients in the adoptive immunotherapy arm had a 41% decreased risk of recurrence and significantly longer RFS; however, OS was not different. Tumor-directed vaccines also showed moderate success as adjuvant therapy, decreasing tumor recurrence rates and increasing recurrence-free and OS[101,102]. In 2009, Hui *et al*[103] published on the results of adjuvant immunotherapy with cytokine-induced killer cells following HCC resection. While there was no difference in survival, patients in the immunotherapy group experienced a decrease in the rate of metastasis formation. However, in a 2015 study by Lee *et al*[104] using autologous cytokine induce killer T-cells and NK cells, the researchers reported increased RFS and OS in the immunotherapy group compared to no adjuvant therapy, though a minority of patients underwent surgery in the study.

The recent discovery of PD-1 and PD-L1 upregulation in tumor infiltrating lymphocytes in HCC and HCC-associated Kupffer cells[105-107], as well as promising results in patients with advanced HCC, has renewed interest in the use of these checkpoint inhibitors as adjuvant therapy following resection[62,65,108]. Unfortunately, there are no published randomized trials evaluating this approach and most of the current trials are evaluating the outcomes of patients with advanced disease[68-70,109]. However, the CheckMate 9DX is an ongoing trial evaluating the use of adjuvant Nivolumab in patients with HCC who are at high risk of recurrence after curative resection or ablation[110, 111]. The findings of this trial are greatly anticipated.

***Hepatic artery infusion pump***

While hepatic arterial infusion (HAI) therapy is more commonly used in the management of colorectal liver metastases[112], its role in HCC remains limited[113]. Nevertheless, at least one study has evaluated the role of HAI as adjuvant therapy following HCC resection. In this retrospective study (42 patients in each group), the investigators compared patients who received HAI chemotherapy to those who received no adjuvant treatment following curative resection for HCC and reported decreased intrahepatic recurrence, decreased RFS and OS at 5 years in patients who received HAI pump chemotherapy. The chemotherapeutic regimen: 5-fluorouracil (1000 mg/m2), oxaliplatin (85 mg/m2), and mitomycin-C (6 mg/m2) was used in this trial, and started within 3 wk of surgery[114]. As noted above, this treatment option is rarely used in clinical practice for HCC management.

***TACE***

While TACE is primarily used in the neoadjuvant setting and for patients with unresectable disease, it has also been evaluated as an adjuvant regimen following resection, though with mixed results. Wang et al reported a phase III RCT of 280 high-risk patients with HBV-related HCC who were randomized to TACE or surveillance following curative hepatectomy. Patients in the TACE arm had significantly less recurrence and longer RFS and OS[115]. However, another trial involving low-risk patients was unable to reproduce these findings [116]. Multiple large single-institution studies have also found a benefit for TACE in patients with risk factors for recurrence[117-119]. Additionally, data from various meta-analyses and systematic reviews of the randomized studies in adjuvant TACE treatment suggest that this regimen may be of benefit in high-risk patients (tumor > 5 cm or vascular invasion). However, there does not appear to be any benefit in low-risk patients (see table below)[22,120-123]. While randomized controlled trials are rare, the findings from the current studies suggest adjuvant TACE treatment might be of benefit in resected patients at high risk for recurrence (Table 2).

***Radiolabeled lipiodol***

Lipiodol, derived from poppy seed, has been used as a radiotracer and contrast dye since the 1920s, including in the imaging of hepatic cancers[124]. In 1979, Nakakuma *et al*[125] reported on the ability of lipiodol to accumulate in HCC relative to normal liver. Injection of the molecule into the hepatic artery resulted in tumor necrosis, and therefore it was investigated as a treatment for HCC with promising results[126,127]. Further use of radiolabeled lipiodol has also been investigated in the adjuvant setting. In 2000, Partensky *et al*[128] conducted a phase 2 study evaluating the role of lipiodol in the adjuvant setting, confirming its safety and potential benefits. A prospective randomized trial by Lau *et al*[129,130] found that adjuvant radiolabeled lipiodol (131I-Lipiodol) following resection of HCC was associated with improved DFS and OS. These findings have been replicated in other retrospective studies and meta-analyses[131-133]. Overall, the current data strongly favor the use of intra-arterial radiolabeled lipiodol as adjuvant therapy for HCC. However, this approach is not routinely used in clinical practice and requires further validation from large RCTs in order to be incorporated into practice.

***Ablation***

Tumor ablation is a form of local-regional directed therapy in patients with non-metastatic disease. Local ablation can include radiofrequency ablation (RFA)[134,135], percutaneous ethanol injection (PEI)[136-139], microwave ablation[140-142] or irreversible electroporation[143-145]. There is insufficient evidence supporting the use of one approach over the other[140,146], and as such the choice of local ablation therapy is primarily driven by institutional expertise. Ablation is typically used as either definitive therapy or as a bridging therapy to LT, enabling patients to either remain within the Milan criteria[16,147-149] or be downstaged to meet criteria[150, 151]. As an adjuvant regimen, it can allow for the extension of the resection margin following tumor resection or debulking[152-155]. In some cases, it can be combined with resection, where the majority of the tumor is resected, and satellite nodules are ablated[156,157]. This combination has been associated with decreased recurrence and improved long-term survival.

***Radiation therapy***

While radiation therapy (RT) had traditionally been avoided in the liver due to the risk of radiation-induced liver disease and limited response, advances in technology and understanding of dose-volume effects has allowed for the use stereotactic body radiation (SBRT) in the management of HCC, primarily in patients with no other standard options but also as an adjunct to other therapeutic therapies[158-160]. While there is limited data on its use as a neoadjuvant or adjuvant therapy to surgical resection, it might be of benefit in patients where adequate margins are not attainable[161]. Some studies have suggested that adjuvant RT might be better than TACE with respect to RFS and OS[162]. However, a recent retrospective analysis of the SEER database showed preoperative radiation therapy had better outcomes (OS) compared to adjuvant RT[163]. Overall, while there is great interest in the use of SBRT as a bridge to transplantation[164-166], its use as an adjunct to surgical resection remains underexplored.

**CONCLUSION**

HCC remains a challenging disease, with an increasing global incidence and high associated mortality. Resection remains an important curative-intent treatment that should be pursued for patients with resectable disease and appropriate liver function. Multimodality therapy is increasingly being explored in order to increase the number of patients who are surgical candidates as well as decrease the incidence of disease recurrence. Unfortunately, due to the paucity of conclusive literature on the subject, current NCCN guidelines do not recommend for or against the routine use of (neo)adjuvant strategies in HCC resection.

While more commonly used as a bridging therapy prior to LT[94], neoadjuvant transarterial therapies can successfully downstage some patients with advanced tumors to resection. There is insufficient evidence to directly compare preoperative TACE versus TARE though radioembolization with Y-90 has the advantage of stimulating contralateral hypertrophy of the FLR without the need for PVE. Long-term outcomes are improved among those patients who experience a response to neoadjuvant therapy. A major challenge in performing research on neoadjuvant treatments is defining the intent of therapy (*e.g.*, definitive, downstaging, or bridge to transplantation) *a priori.* Future research would benefit from well-designed prospective studies that clearly define goals of treatment and carefully measure short- and long-term outcomes. Following resection, based on a large phase III RCT, adjuvant Sorafenib is not recommended, but there is insufficient evidence to support the use of other adjuvant therapies. For those patients with HCC in the setting of viral hepatitis, aggressive treatment with antivirals, before or after resection, improves outcomes and should be pursued. The outcomes of these therapies reflect the different mechanisms of HCC recurrence following surgical resection: multicentric carcinogenesis *vs* intrahepatic metastasis. While antiviral therapies are effective in decreasing neocarcinogenesis, they have less impact on intrahepatic metastases. Cytotoxic therapies aim to decrease recurrence from intrahepatic metastases, but to date have demonstrated limited effectiveness.. The development of more effective targeted and immune-based therapies will hopefully lead to significant advances in recurrence rates.

In conclusion, the optimal multidisciplinary management of HCC continues to rapidly evolve. While surgical resection remains an important treatment option for patients with HCC, the addition of neoadjuvant and/or adjuvant treatment strategies may increase the proportion of patients who are surgical candidates and improve the long-term outcomes of those who undergo surgery. With exciting advances in locoregional and systemic therapies, including developments in immunotherapy, future research will be needed to identify the optimal components of multimodality therapy.

**REFERENCES**

1 **Global Burden of Disease Cancer Collaboration**, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. *JAMA Oncol* 2015; **1**: 505-527 [PMID: 26181261 DOI: 10.1001/jamaoncol.2015.0735]

2 **Global Burden of Disease Liver Cancer Collaboration**, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. *JAMA Oncol* 2017; **3**: 1683-1691 [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055]

3 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

4 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

5 **Beal EW**, Tumin D, Kabir A, Moris D, Zhang XF, Chakedis J, Washburn K, Black S, Schmidt CM, Pawlik TM. Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA. *World J Surg* 2018; **42**: 835-840 [PMID: 28879603 DOI: 10.1007/s00268-017-4194-1]

6 **El-Serag HB**, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? *Hepatology* 2014; **60**: 1767-1775 [PMID: 24839253 DOI: 10.1002/hep.27222]

7 **Wands J**. Hepatocellular carcinoma and sex. *N Engl J Med* 2007; **357**: 1974-1976 [PMID: 17989393 DOI: 10.1056/NEJMcibr075652]

8 **Maucort-Boulch D**, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. *Int J Cancer* 2018; **142**: 2471-2477 [PMID: 29388206 DOI: 10.1002/ijc.31280]

9 **Davila JA**, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. *Gastroenterology* 2004; **127**: 1372-1380 [PMID: 15521006 DOI: 10.1053/j.gastro.2004.07.020]

10 **Hashimoto E**, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Gastroenterol* 2009; **44** Suppl 19: 89-95 [PMID: 19148800 DOI: 10.1007/s00535-008-2262-x]

11 **Mittal S**, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol* 2013; **47** Suppl: S2-S6 [PMID: 23632345 DOI: 10.1097/MCG.0b013e3182872f29]

12 **Chu YJ**, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. *Int J Cancer* 2017; **141**: 711-720 [PMID: 28509392 DOI: 10.1002/ijc.30782]

13 **El-Serag HB**, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol* 2006; **4**: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007]

14 **Liu Y**, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. *Environ Health Perspect* 2010; **118**: 818-824 [PMID: 20172840 DOI: 10.1289/ehp.0901388]

15 **Ko C**, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH, Gordon FD, Schilsky ML, Kowdley KV. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. *Liver Int* 2007; **27**: 1394-1401 [PMID: 17927713 DOI: 10.1111/j.1478-3231.2007.01596.x]

16 **Pompili M**, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. *Liver Transpl* 2005; **11**: 1117-1126 [PMID: 16123960 DOI: 10.1002/lt.20469]

17 **Tabrizian P**, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. *Ann Surg* 2015; **261**: 947-955 [PMID: 25010665 DOI: 10.1097/SLA.0000000000000710]

18 **Lencioni R**, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. *Semin Intervent Radiol* 2013; **30**: 3-11 [PMID: 24436512 DOI: 10.1055/s-0033-1333648]

19 **Monden M**, Okamura J, Sakon M, Gotoh M, Kobayashi K, Umeshita K, Yamada T, Kuroda C, Sakurai M, Mori T. Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas. *Cancer Chemother Pharmacol* 1989; **23** Suppl: S90-S95 [PMID: 2538272 DOI: 10.1007/BF00647249]

20 **Zhang Z**, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. *Cancer* 2000; **89**: 2606-2612 [PMID: 11135222 DOI: 10.1002/1097-0142(20001215)89:12<2606::AID-CNCR13>3.0.CO;2-T]

21 **Jianyong L**, Jinjing Z, Wentao W, Lunan Y, Qiao Z, Bo L, Tianfu W, Minqing X, Jiaying Y, Yongang W. Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis. *Ann Hepatol* 2014; **13**: 394-402 [PMID: 24927610]

22 **Qi X**, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. *Oncotarget* 2015; **6**: 36838-36859 [PMID: 26451613 DOI: 10.18632/oncotarget.5426]

23 **Fan J**, Tang ZY, Yu YQ, Wu ZQ, Ma ZC, Zhou XD, Zhou J, Qiu SJ, Lu JZ. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. *Dig Surg* 1998; **15**: 674-678 [PMID: 9845635 DOI: 10.1159/000018676]

24 **Lau WY**, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. *Ann Surg* 2004; **240**: 299-305 [PMID: 15273555 DOI: 10.1097/01.sla.0000133123.11932.19]

25 **Lau WY**, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. *Ann Surg Oncol* 2007; **14**: 3301-3309 [PMID: 17891443 DOI: 10.1245/s10434-007-9549-7]

26 **Zhang Y**, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. *Oncologist* 2016; **21**: 1442-1449 [PMID: 27486202 DOI: 10.1634/theoncologist.2016-0094]

27 **Tao Q**, He W, Li B, Zheng Y, Zou R, Shen J, Liu W, Zhang Y, Yuan Y. Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence. *J Cancer* 2018; **9**: 2778-2785 [PMID: 30123345 DOI: 10.7150/jca.25033]

28 **Aoki T**, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. *Arch Surg* 2004; **139**: 766-774 [PMID: 15249411 DOI: 10.1001/archsurg.139.7.766]

29 **Ogata S**, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. *Br J Surg* 2006; **93**: 1091-1098 [PMID: 16779884 DOI: 10.1002/bjs.5341]

30 **Yoo H**, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG, Hwang S. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. *Ann Surg Oncol* 2011; **18**: 1251-1257 [PMID: 21069467 DOI: 10.1245/s10434-010-1423-3]

31 **Pompili M**, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. *World J Gastroenterol* 2013; **19**: 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515]

32 **Kallini JR**, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. *Adv Ther* 2016; **33**: 699-714 [PMID: 27039186 DOI: 10.1007/s12325-016-0324-7]

33 **Salem R**, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 497-507.e2 [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049]

34 **Gaba RC**, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. *Ann Surg Oncol* 2009; **16**: 1587-1596 [PMID: 19357924 DOI: 10.1245/s10434-009-0454-0]

35 **Vouche M**, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. *J Hepatol* 2013; **59**: 1029-1036 [PMID: 23811303 DOI: 10.1016/j.jhep.2013.06.015]

36 **Braat AJ**, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. *Front Oncol* 2014; **4**: 199 [PMID: 25126539 DOI: 10.3389/fonc.2014.00199]

37 **Lewandowski RJ**, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. *J Surg Oncol* 2016; **114**: 99-105 [PMID: 27103352 DOI: 10.1002/jso.24269]

38 **Bouazza F**, Poncelet A, Garcia CA, Delatte P, Engelhom JL, Gomez Galdon M, Deleporte A, Hendlisz A, Vanderlinden B, Flamen P, Donckier V. Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma. *World J Gastroenterol* 2015; **21**: 9666-9670 [PMID: 26327775 DOI: 10.3748/wjg.v21.i32.9666]

39 **Lewandowski RJ**, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant* 2009; **9**: 1920-1928 [PMID: 19552767 DOI: 10.1111/j.1600-6143.2009.02695.x]

40 **European Association for the Study of the Liver**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

41 **Heimbach JK**, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018; **67**: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29086]

42 **Omata M**, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; **11**: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

43 **Benson AB 3rd**, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. *J Natl Compr Canc Netw* 2017; **15**: 563-573 [PMID: 28476736]

44 **Schwarz RE**, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. *HPB* (Oxford) 2010; **12**: 313-320 [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x]

45 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

46 **Marrero JA**, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. *J Hepatol* 2016; **65**: 1140-1147 [PMID: 27469901 DOI: 10.1016/j.jhep.2016.07.020]

47 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

48 **Wilhelm SM**, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004; **64**: 7099-7109 [PMID: 15466206 DOI: 10.1158/0008-5472.CAN-04-1443]

49 **Ito Y**, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. *Hepatology* 1998; **27**: 951-958 [PMID: 9537433 DOI: 10.1002/hep.510270409]

50 **Vitale A**, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. *Hepatology* 2010; **51**: 165-173 [PMID: 19877181 DOI: 10.1002/hep.23260]

51 **Hoffmann K**, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. *BMC Cancer* 2008; **8**: 349 [PMID: 19036146 DOI: 10.1186/1471-2407-8-349]

52 **Irtan S**, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. *Liver Int* 2011; **31**: 740-743 [PMID: 21457447 DOI: 10.1111/j.1478-3231.2010.02441.x]

53 **Barbier L**, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. *Int J Hepatol* 2011; **2011**: 791013 [PMID: 22135750 DOI: 10.4061/2011/791013]

54 **Bouattour M**, Fartoux L, Rosmorduc O, Scatton O, Vibert E, Costentin C, Soubrane O, Ronot M, Granier MM, De Gramont A, Belghiti J, Paradis V, Wendum D, Tijeras-Raballand A, Hadengue A, Brusquant D, Chibaudel B, Raymond E, Faivre SJ. BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC. *J Clin Oncol* 2016; **34**: 252-252 [DOI: 10.1200/jco.2016.34.4\_suppl.252]

55 **Boschetti G**, Walter T, Hervieu V, Cassier P, Lombard-Bohas C, Adham M, Scoazec JY, Dumortier J. Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? *Eur J Gastroenterol Hepatol* 2010; **22**: 1015-1018 [PMID: 20075738 DOI: 10.1097/MEG.0b013e328336565a]

56 **Abou-Alfa GK**, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *JAMA* 2010; **304**: 2154-2160 [PMID: 21081728 DOI: 10.1001/jama.2010.1672]

57 **Abou-Alfa GK**, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, Siegel A, Balletti J, Harding JJ, Schwartz LH, Goldberg RM, Bertagnolli MM, Venook AP. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). *J Clin Oncol* 2016; **34**: 192-192 [DOI: 10.1200/jco.2016.34.4\_suppl.192]

58 **Kudo M**, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; **391**: 1163-1173 [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1]

59 **Abou-Alfa GK**, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N Engl J Med* 2018; **379**: 54-63 [PMID: 29972759 DOI: 10.1056/NEJMoa1717002]

60 **Bruix J**, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **389**: 56-66 [PMID: 27932229 DOI: 10.1016/S0140-6736(16)32453-9]

61 **Gilabert M**, Raoul JL. Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. *J Hepatocell Carcinoma* 2018; **5**: 91-98 [PMID: 30464931 DOI: 10.2147/JHC.S157413]

62 **El-Khoueiry AB**, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet* 2017; **389**: 2492-2502 [PMID: 28434648 DOI: 10.1016/S0140-6736(17)31046-2]

63 **Sangro B,** Yau T, Hsu C, Kudo M, Crocenzi TS, Choo SP, Meyer T, Welling TH, III, Yeo W, Chopra A, Baakili A, dela Cruz C, Lang L, Neely J, Melero I, El-Khoueiry AB, Trojan J. Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study. Journal of Hepatology 2017; 66(1): S34-S35 [DOI: 10.1016/S0168-8278(17)30329-X]

64 **Zhu AX**, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol* 2018; **19**: 940-952 [PMID: 29875066 DOI: 10.1016/S1470-2045(18)30351-6]

65 **Sangro B**, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol* 2013; **59**: 81-88 [PMID: 23466307 DOI: 10.1016/j.jhep.2013.02.022]

66 **Stein S**, Pishvaian MJ, Lee MS, Lee K-H, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K, Ryoo B-Y. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). *J Clin Oncol* 2018; **36**: 4074-4074 [DOI: 10.1200/JCO.2018.36.15\_suppl.4074]

67 **Chen Y**, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. *Hepatobiliary Pancreat Dis Int* 2018; **17**: 301-309 [PMID: 29861325 DOI: 10.1016/j.hbpd.2018.05.005]

68 **Finn RS**, Chan SL, Zhu AX, Knox JJ, Cheng A-L, Siegel AB, Bautista O, Watson P, Kudo M. KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma. *J Clin Oncol* 2017; **35**: TPS503-TPS503 [DOI: 10.1200/JCO.2017.35.4\_suppl.TPS503]

69 **Sangro B,** Park J-W, Dela Cruz CM, Anderson J, Lang L, Neely J, Shaw JW, Cheng A-L. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. *J Clin Oncol* 2016; **34**: TPS4147-TPS4147 [DOI: 10.1200/JCO.2016.34.15\_suppl.TPS4147]

70 **Abou-Alfa GK,** Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Negro A, Sangro B. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. *J Clin Oncol* 2018; **36**: TPS4144-TPS4144 [DOI: 10.1200/JCO.2018.36.15\_suppl.TPS4144]

71 **Sohn W**, Paik YH, Kim JM, Kwon CH, Joh JW, Cho JY, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. *Ann Surg Oncol* 2014; **21**: 2429-2435 [PMID: 24619495 DOI: 10.1245/s10434-014-3621-x]

72 **Huang G**, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. *Ann Surg* 2015; **261**: 56-66 [PMID: 25072444 DOI: 10.1097/SLA.0000000000000858]

73 **Li Z**, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. *JAMA Surg* 2018; **153**: e182721 [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721]

74 **Zhang B**, Xu D, Wang R, Zhu P, Mei B, Wei G, Xiao H, Zhang B, Chen X. Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. *Int J Surg* 2015; **15**: 1-5 [PMID: 25596447 DOI: 10.1016/j.ijsu.2014.12.030]

75 **Kubo S**, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. *Ann Intern Med* 2001; **134**: 963-967 [PMID: 11352697 DOI: 10.7326/0003-4819-134-10-200105150-00010]

76 **Nishiguchi S**, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. *Intervirology* 2005; **48**: 71-75 [PMID: 15785093 DOI: 10.1159/000082098]

77 **Kubo S**, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg* 2002; **89**: 418-422 [PMID: 11952580 DOI: 10.1046/j.0007-1323.2001.02054.x]

78 **Hsu YC**, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. *Hepatology* 2013; **58**: 150-157 [PMID: 23389758 DOI: 10.1002/hep.26300]

79 **Lee D**, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. *Cancer* 2013; **119**: 2239-2246 [PMID: 23564564 DOI: 10.1002/cncr.28082]

80 **Wu J**, Yin Z, Cao L, Xu X, Yan T, Liu C, Li D. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis. *Medicine (Baltimore)* 2018; **97**: e11295 [PMID: 29995763 DOI: 10.1097/MD.0000000000011295]

81 **Virlogeux V**, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres AC, Ducerf C, Mabrut JY, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. *Liver Int* 2017; **37**: 1122-1127 [PMID: 28423231 DOI: 10.1111/liv.13456]

82 **Spengler U**. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. *Pharmacol Ther* 2018; **183**: 118-126 [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009]

83 **Zhou Y**, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. *World J Surg Oncol* 2011; **9**: 108 [PMID: 21933440 DOI: 10.1186/1477-7819-9-108]

84 **Reig M**, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016; **65**: 719-726 [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008]

85 **Singal AG**, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. *Gastroenterology* 2019; **156**: 1683-1692.e1 [PMID: 30660729 DOI: 10.1053/j.gastro.2019.01.027]

86 **Cabibbo G**, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol* 2019 [PMID: 30959157 DOI: 10.1016/j.jhep.2019.03.027]

87 **Nault JC**, Nahon P. Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence? *Gastroenterology* 2019; **156**: 1558-1560 [PMID: 30926345 DOI: 10.1053/j.gastro.2019.03.027]

88 **Yin J**, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. *J Clin Oncol* 2013; **31**: 3647-3655 [PMID: 24002499 DOI: 10.1200/JCO.2012.48.5896]

89 **Chuma M**, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. *J Gastroenterol* 2009; **44**: 991-999 [PMID: 19554391 DOI: 10.1007/s00535-009-0093-z]

90 **Wu CY**, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. *JAMA* 2012; **308**: 1906-1914 [PMID: 23162861 DOI: 10.1001/2012.jama.11975]

91 **Yang T**, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. *Eur J Surg Oncol* 2012; **38**: 683-691 [PMID: 22621971 DOI: 10.1016/j.ejso.2012.04.010]

92 **Huang G**, Li PP, Lau WY, Pan ZY, Zhao LH, Wang ZG, Wang MC, Zhou WP. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. *Ann Surg* 2018; **268**: 943-954 [PMID: 29521740 DOI: 10.1097/SLA.0000000000002727]

93 **Akateh C**, Pawlik TM, Cloyd JM. Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B? *Ann Transl Med* 2018; **6**: 397 [PMID: 30498725 DOI: 10.21037/atm.2018.08.20]

94 **NCCN**. Hepatobiliary Cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2019: Version 1. Available from: https://www.nccn.org/professionals/physician\_gls/default.aspx

95 **Yamamoto M**, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. *Br J Surg* 1996; **83**: 336-340 [PMID: 8665186 DOI: 10.1002/bjs.1800830313]

96 **Ono T**, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. *Cancer* 2001; **91**: 2378-2385 [PMID: 11413528 DOI: 10.1002/1097-0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2]

97 **Wang J**, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. *Can J Gastroenterol* 2013; **27**: 351-363 [PMID: 23781519 DOI: 10.1155/2013/417894]

98 **Lai EC**, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. *Arch Surg* 1998; **133**: 183-188 [PMID: 9484732 DOI: 10.1001/archsurg.133.2.183]

99 **Bruix J**, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015; **16**: 1344-1354 [PMID: 26361969 DOI: 10.1016/S1470-2045(15)00198-9]

100 **Takayama T**, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet* 2000; **356**: 802-807 [PMID: 11022927 DOI: 10.1016/S0140-6736(00)02654-4]

101 **Kuang M**, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. *Clin Cancer Res* 2004; **10**: 1574-1579 [PMID: 15014006 DOI: 10.1158/1078-0432.CCR-03-0071]

102 **Peng BG**, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF. Tumor vaccine against recurrence of hepatocellular carcinoma. *World J Gastroenterol* 2005; **11**: 700-704 [PMID: 15655825 DOI: 10.3748/wjg.v11.i5.700]

103 **Hui D**, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. *Dig Liver Dis* 2009; **41**: 36-41 [PMID: 18818130 DOI: 10.1016/j.dld.2008.04.007]

104 **Lee JH**, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. *Gastroenterology* 2015; **148**: 1383-91.e6 [PMID: 25747273 DOI: 10.1053/j.gastro.2015.02.055]

105 **Wu K**, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. *Cancer Res* 2009; **69**: 8067-8075 [PMID: 19826049 DOI: 10.1158/0008-5472.CAN-09-0901]

106 **Shi F**, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. *Int J Cancer* 2011; **128**: 887-896 [PMID: 20473887 DOI: 10.1002/ijc.25397]

107 **Lu LC**, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. *Liver Cancer* 2019; **8**: 110-120 [PMID: 31019901 DOI: 10.1159/000489021]

108 **FDA CDER-**. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. approved Drugs: Center for Drug Evaluation and Research, 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib

109 **Finn RS,** Ducreux M, Qin S, Galle PR, Zhu AX, Ikeda M, Kim T-Y, Xu D-Z, Verret W, Liu J, Grossman W, Cheng A-L. IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. Journal of Clinical Oncology 2018; 36(15\_suppl): TPS4141-TPS4141 [DOI: 10.1200/JCO.2018.36.15\_suppl.TPS4141]

110 **ClinicalTrials.gov**. An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma - Full Text View - ClinicalTrials.gov. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02576509

111 **Jimenez Exposito MJ,** Akce M, Montero Alvarez JL, Assenat E, Balart LA, Baron AD, Decaens T, Heurgue-Berlot A, Martin AO, Paik SW, Poulart V, Sehbai AS, Takemura N, Yoon JH. 783TiP CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. Annals of Oncology 2018; 29(suppl\_8) [DOI: 10.1093/annonc/mdy282.166]

112 **Venook AP,** Curley SA. Management of potentially resectable colorectal cancer liver metastases. In: Tanabe KK, editor: UpToDate, 2019. https://www.uptodate.com/contents/management-of-potentially-resectable-colorectal-cancer-liver-metastases

113 **Song MJ**. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. *World J Gastroenterol* 2015; **21**: 3843-3849 [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843]

114 **Feng M**, Tang C, Feng W, Bao Y, Zheng Y, Shen J. Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy. *Onco Targets Ther* 2017; **10**: 3001-3005 [PMID: 28652782 DOI: 10.2147/OTT.S136806]

115 **Wang Z**, Ren Z, Chen Y, Hu J, Yang G, Yu L, Yang X, Huang A, Zhang X, Zhou S, Sun H, Wang Y, Ge N, Xu X, Tang Z, Lau W, Fan J, Wang J, Zhou J. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. *Clin Cancer Res* 2018; **24**: 2074-2081 [PMID: 29420221 DOI: 10.1158/1078-0432.CCR-17-2899]

116 **Zhai XF**, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study. *Cancer*2018; **124**: 2161-2168 [PMID: 29499082 DOI: 10.1002/cncr.30915]

117 **Li C**, Wen TF, Yan LN, Lu WS, Li B, Wang WT, Xu MQ, Yang JY. Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria. *J Surg Res* 2017; **209**: 8-16 [PMID: 28032575 DOI: 10.1016/j.jss.2016.09.054]

118 **Liu C**, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. *World J Surg Oncol* 2016; **14**: 100 [PMID: 27038790 DOI: 10.1186/s12957-016-0855-z]

119 **Xi T**, Lai EC, Min AR, Shi LH, Wu D, Xue F, Wang K, Yan Z, Xia Y, Shen F, Lau WY, Wu MC. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. *Hepatogastroenterology* 2012; **59**: 1198-1203 [PMID: 22580673 DOI: 10.5754/hge09654]

120 **Samuel M**, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. *Cochrane Database Syst Rev*2009; : CD001199 [PMID: 19160192 DOI: 10.1002/14651858.CD001199.pub2]

121 **Zhong JH**, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. *Hepatol Res* 2010; **40**: 943-953 [PMID: 20887328 DOI: 10.1111/j.1872-034X.2010.00710.x]

122 **Cheng X**, Sun P, Hu QG, Song ZF, Xiong J, Zheng QC. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. *J Cancer Res Clin Oncol* 2014; **140**: 1159-1170 [PMID: 24752339 DOI: 10.1007/s00432-014-1677-4]

123 **Liao M**, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. *Scand J Gastroenterol* 2017; **52**: 624-634 [PMID: 28276833 DOI: 10.1080/00365521.2017.1292365]

124 **Idezuki Y**, Sugiura M, Hatano S, Kimoto S. Hepatography for detection of small tumor masses in liver: experiences with oily contrast medium. *Surgery* 1966; **60**: 566-572 [PMID: 5913780]

125 **Nakakuma K**, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y, Yokoyama I. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. *Cancer* 1983; **52**: 2193-2200 [PMID: 6196102 DOI: 10.1002/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO;2-R]

126 **Raoul JL**, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. *J Nucl Med* 1994; **35**: 1782-1787 [PMID: 7525901]

127 **Park CH**, Suh JH, Yoo HS, Lee JT, Kim DI, Kim BS. Treatment of hepatocellular carcinoma (HCC) with radiolabeled Lipiodol: a preliminary report. *Nucl Med Commun* 1987; **8**: 1075-1087 [PMID: 2835716]

128 **Partensky C**, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. *Arch Surg* 2000; **135**: 1298-1300 [PMID: 11074884 DOI: 10.1001/archsurg.135.11.1298]

129 **Lau WY**, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. *Ann Surg* 2008; **247**: 43-48 [PMID: 18156922 DOI: 10.1097/SLA.0b013e3181571047]

130 **Lau WY**, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. *Lancet* 1999; **353**: 797-801 [PMID: 10459961 DOI: 10.1016/S0140-6736(98)06475-7]

131 **Furtado R**, Crawford M, Sandroussi C. Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma. *Ann Surg Oncol* 2014; **21**: 2700-2707 [PMID: 24743904 DOI: 10.1245/s10434-014-3511-2]

132 **Furtado RV**, Ha L, Clarke S, Sandroussi C. Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma. *J Oncol* 2015; **2015**: 746917 [PMID: 26713092 DOI: 10.1155/2015/746917]

133 **Lambert B**, Praet M, Vanlangenhove P, Troisi R, de Hemptinne B, Gemmel F, Van Vlierberghe H, Van de Wiele C. Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome. *Cancer Biother Radiopharm* 2005; **20**: 209-214 [PMID: 15869457 DOI: 10.1089/cbr.2005.20.209]

134 **Curley SA**, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. *Ann Surg* 1999; **230**: 1-8 [PMID: 10400029 DOI: 10.1097/00000658-199907000-00001]

135 **Amersi FF**, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. *Arch Surg* 2006; **141**: 581-587; discussion 587-588 [PMID: 16785359 DOI: 10.1001/archsurg.141.6.581]

136 **Shiina S**, Yasuda H, Muto H, Tagawa K, Unuma T, Ibukuro K, Inoue Y, Takanashi R. Percutaneous ethanol injection in the treatment of liver neoplasms. *AJR Am J Roentgenol*1987; **149**: 949-952 [PMID: 2823586 DOI: 10.2214/ajr.149.5.949]

137 **Sugiura N,** Takara K, Ohto M, Okuda K, Hirooka N. Ultrasound image-guided percutaneous intratumor ethanol injection for small hepatocellular carcinoma. Acta Hepatol Jpn 1983; 24: 920 [DOI: 10.2957/kanzo.24.920]

138 **Livraghi T**, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. *Radiology* 1986; **161**: 309-312 [PMID: 3020612 DOI: 10.1148/radiology.161.2.3020612]

139 **Shiina S**, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, Hata Y, Niwa Y, Shiratori Y, Terano A. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. *Cancer* 1991; **68**: 1524-1530 [PMID: 1654196 DOI: 10.1002/1097-0142(19911001)68:7<1524::AID-CNCR2820680711>3.0.CO;2-O]

140 **Shibata T**, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002; **223**: 331-337 [PMID: 11997534 DOI: 10.1148/radiol.2232010775]

141 **Seki T**, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, Nishimura A, Yamashiki N, Okamura A, Inoue K. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. *Cancer* 1999; **85**: 1694-1702 [PMID: 10223562 DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1694::AID-CNCR8>3.0.CO;2-3]

142 **Lubner MG**, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. *J Vasc Interv Radiol* 2010; **21**: S192-S203 [PMID: 20656229 DOI: 10.1016/j.jvir.2010.04.007]

143 **Lee EW**, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. *Radiology* 2010; **255**: 426-433 [PMID: 20413755 DOI: 10.1148/radiol.10090337]

144 **Edd JF**, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. *IEEE Trans Biomed Eng* 2006; **53**: 1409-1415 [PMID: 16830945 DOI: 10.1109/TBME.2006.873745]

145 **Kingham TP**, Karkar AM, D'Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB, Jarnagin WR, Fong Y. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. *J Am Coll Surg* 2012; **215**: 379-387 [PMID: 22704820 DOI: 10.1016/j.jamcollsurg.2012.04.029]

146 **Lu MD**, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, Xu ZF, Liu GJ, Zheng YL. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. *J Gastroenterol* 2005; **40**: 1054-1060 [PMID: 16322950 DOI: 10.1007/s00535-005-1671-3]

147 **Fontana RJ**, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. *Liver Transpl* 2002; **8**: 1165-1174 [PMID: 12474157 DOI: 10.1053/jlts.2002.36394]

148 **Lu DS**, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *Hepatology* 2005; **41**: 1130-1137 [PMID: 15841454 DOI: 10.1002/hep.20688]

149 **Mazzaferro V**, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg* 2004; **240**: 900-909 [PMID: 15492574 DOI: 10.1097/01.sla.0000143301.56154.95]

150 **Barakat O**, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, Toombs B, Round M, Moore W, Mieles L. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. *Liver Transpl* 2010; **16**: 289-299 [PMID: 20209588 DOI: 10.1002/lt.21994]

151 **Yao FY**, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology* 2008; **48**: 819-827 [PMID: 18688876 DOI: 10.1002/hep.22412]

152 **Pawlik TM**, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. *Ann Surg Oncol*2003; **10**: 1059-1069 [PMID: 14597445 DOI: 10.1245/ASO.2003.03.026]

153 **Eisele RM**, Zhukowa J, Chopra S, Schmidt SC, Neumann U, Pratschke J, Schumacher G. Results of liver resection in combination with radiofrequency ablation for hepatic malignancies. *Eur J Surg Oncol* 2010; **36**: 269-274 [PMID: 19726155 DOI: 10.1016/j.ejso.2009.07.188]

154 **Poon RT**. Radiofrequency ablation combined with resection enhances chance for curative treatment of hepatocellular carcinoma. *Ann Surg Oncol* 2007; **14**: 3299-3300 [PMID: 17899286 DOI: 10.1245/s10434-007-9567-5]

155 **Reich DJ**. Liver resection after thermal ablation of parenchymal transection margin using microwave energy. *Clin Liver Dis* (Hoboken) 2015; **5**: 25-28 [PMID: 31040942 DOI: 10.1002/cld.450]

156 **Xu LL**, Zhang M, Yi PS, Zheng XB, Feng L, Lan C, Tang JW, Ren SS, Xu MQ. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. *J Huazhong Univ Sci Technolog Med Sci* 2017; **37**: 974-980 [PMID: 29270762 DOI: 10.1007/s11596-017-1836-3]

157 **Lee SJ**, Cho EH, Kim R, Kim YH, Lim CS, Kim SB. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. *Korean J Hepatobiliary Pancreat Surg* 2015; **19**: 98-102 [PMID: 26379730 DOI: 10.14701/kjhbps.2015.19.3.98]

158 **Bettinger D,** Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2018 [DOI: 10.1159/000490260]

159 **Park HC**, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. *Liver Cancer* 2016; **5**: 162-174 [PMID: 27493892 DOI: 10.1159/000367766]

160 **Yamada K**, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2003; **57**: 113-119 [PMID: 12909223 DOI: 10.1016/S0360-3016(03)00434-6]

161 **Wang WH**, Wang Z, Wu JX, Zhang T, Rong WQ, Wang LM, Jin J, Wang SL, Song YW, Liu YP, Ren H, Fang H, Wang WQ, Liu XF, Yu ZH, Li YX. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. *Liver Int* 2015; **35**: 2603-2610 [PMID: 25939444 DOI: 10.1111/liv.12857]

162 **Wang L**, Wang W, Yao X, Rong W, Wu F, Chen B, Liu M, Lin S, Liu Y, Wu J. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion. *Oncotarget* 2017; **8**: 79971-79981 [PMID: 29108379 DOI: 10.18632/oncotarget.20402]

163 **Lin H**, Li X, Liu Y, Hu Y. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma. *ANZ J Surg* 2018; **88**: E718-E724 [PMID: 29399938 DOI: 10.1111/ans.14387]

164 **Katz AW**, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. *Int J Radiat Oncol Biol Phys* 2012; **83**: 895-900 [PMID: 22172906 DOI: 10.1016/j.ijrobp.2011.08.032]

165 **Mohamed M**, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, Qiu H, Hezel AF, Ramaraju GA, Dokus MK, Orloff MS. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. *Adv Radiat Oncol* 2015; **1**: 35-42 [PMID: 28799575 DOI: 10.1016/j.adro.2015.12.003]

166 **Mannina EM**, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, Cox JA, Saxena R, Tector J, Maluccio M. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. *Int J Radiat Oncol Biol Phys* 2017; **97**: 931-938 [PMID: 28333015 DOI: 10.1016/j.ijrobp.2016.12.036]

167 **Ikeda K**, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. *Hepatology* 2000; **32**: 228-232 [PMID: 10915728 DOI: 10.1053/jhep.2000.9409]

168 **Chong CC**, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee KF, Lai PB, Chan HL. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. *Aliment Pharmacol Ther* 2015; **41**: 199-208 [PMID: 25413146 DOI: 10.1111/apt.13034]

169 **Peng BG**, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. *Am J Surg* 2009; **198**: 313-318 [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026]

170 **Ye JZ**, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. *World J Gastroenterol* 2017; **23**: 7415-7424 [PMID: 29151695 DOI: 10.3748/wjg.v23.i41.7415]

171 **Qi YP**, Zhong JH, Liang ZY, Zhang J, Chen B, Chen CZ, Li LQ, Xiang BD. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. *Am J Surg* 2019; **217**: 739-744 [PMID: 30103903 DOI: 10.1016/j.amjsurg.2018.07.054]

**P-Reviewer:** Suda T, Yamasaki T

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Selected studies on the use of adjuvant antiviral therapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **Arms and Intervention** | **Number of patients** | **Main Outcomes**  | **Comments**  |
| Outcomes of adjuvant interferon-based therapy for HCV-related hepatocellular carcinoma. |
| Ikeda *et al* (2000)[167] | RCT | 36 mo of Interferon (IFN) with 2-yr follow-up | 20 (8 per arm) | IFN treatment decreased tumor recurrence. | Included 4 patients treated with PEI. |
| Kubo *et al* (2001,[75] 2002,[77] 2005[76]) | RCT | 88 weeks of IFN versus no therapy. Median follow up of 1087 days. | 30 (15 per arm) | IFN decreased the recurrence and survival after resection | All male patients with high viral loads. |
| Hsu *et al* (2013)[78] | Retrospective Cohort | PEG-IFN + Ribavirin for > 16 weeks versus no therapy. | 1065 (213 treatment and 852 controls) | PEG-IFN + Ribavirin associated with decrease 1‐, 3‐ and 5‐yr recurrence rate of HCC and 1‐, 3‐ and 5‐yr mortality. | The NNT for one fewer recurrent HCC at 5 yr = 8. Risk attenuation higher in younger patients. |
| Lee *et al* (2013)[79] | Prospective Cohort | PEG-IFN for 12 mo versus no therapy. Median follow up of 24 mo. | 93 (31 treatment and 62 controls) | PEG-IFN associated with decrease 1‐and 2‐year recurrence and higher 1‐ and 2‐year survival. | All patients had MTA1‐positive HCC and high viral levels. |
| Wu et al (2018)[80] | Meta-analysis | PEG-IFN versus no therapy | 4 cohort studies, 1280 patients. 3 studies had 5-year survival data with 276 PEG-IFN and 911 control total. | PEG-IFN improved the 3- and 5-yr RFS and 5-yr OS. | Included data from Hsu *et al*, and Lee *et al* |
| Outcomes of nucleoside analog treatment for HBV related HCC |
| Wu *et al* (2012)[90] | Retrospective Cohort | Nucleoside analog for at least 90 days vs no therapy | 4569 (518 treated and 4051 controls) | Nucleoside analog treatment was associated with a lower risk of HCC recurrence. | Nucleoside analogues included lamivudine, entecavir, and telbivudine |
| Yang *et al* (2012)[91] | Prospective Cohort | Antiviral therapy vs no treatment. | 330 patients (142 treated *vs* 188 untreated). All high viral loads. | Antiviral therapy was associated with RFS and OS. High associated with poor OS and RFS | High viral load (≥ 10000 copies/mL) and low viral load (< 10000 copies/mL). Antiviral included lamivudine, adefovir dipivoxil, or entecavir. |
| Yin *et al* (2013)[88] | Two-stage longitudinal clinical study (RCT and non-RCT) | Nucleoside analog (NA) *vs* no therapy. | 617 in non-RCT (215 treatment and 402 controls).163 in RCT (81 treatment and 82 controls) | NA treatment improved postop liver function, decreased HCC recurrence, and improved postoperative survival | Lamivudine, adefovir dipivoxil, or entecavir. |
| Chong *et al* (2015)[168] | Retrospective cohort | Antiviral therapy *vs* no therapy | 404 (254 antiviral and 150 controls) | Antiviral therapy improves long‐term survival post‐hepatectomy. No difference in early or late recurrence. |  |
| Zhang *et al* (2015)[74] | Retrospective cohort | Entecavir antiviral therapy *vs* no therapy | 112 (72 antiviral and 40 controls) | Antiviral treatment improves morbidity and improved postoperative liver function. | Patients with preop HBV DNA > 104 copies/mL received antiviral therapy as well. |
| Huang *et al* (2015)[72] | RCT | adefovir antiviral therapy vs no therapy | 200 (100 antiviral and 100 controls) | adefovir antiviral therapy reduced late HCC recurrence and improved OS | Patients had high preoperative HBV DNA (> 2000 IU/mL) |
| Huang *et al* (2018)[92] | RCT | Telbivudine antiviral therapy vs no therapy | 200 (100 antiviral and 100 controls) | Telbivudine HCC resulted in better 5-year OS and RFS, as well as a lower rate of HBV reactivation | Patient with low (< 2000 IU/mL) HBV DNA titer. |

HCV: Hepatitis C virus; RCT: Randomized controlled trial; IFN: Interferon; PEI: Percutaneous ethanol injection; PEG-IFN: Pegylated interferon; HCC: Hepatocellular carcinoma; NNT: Number needed to treat; OS: Overall survival; RFS: Recurrence-free survival; NA: Nucleos(t)ide analog; HBV: Hepatitis B virus.

**Table 2 Selected studies on the use of adjuvant transarterial chemotherapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **Arms and intervention** | **Number of patients** | **Main outcomes** | **Comments** |
| Peng *et al* (2009)[169] | Retrospective cohort | LR *vs* LR+TACE | 53 control *vs* 51 treatment (TACE) | Improved 1-, 3- and 5-yr survival with TACE | HCC< 3 cm + portal vein thrombosis |
| Liu *et al* (2016)[118]  | Retrospective cohort | LR *vs* LR+TACE | 55 Control *vs* 62 Treatment | Overall: Improved 1-year OS with TACE, but no difference in 2- and 3-yr DFS rates. | For tumor size > 5 cm: improve 1-, 2- and 3-yr DFS. For tumor size ≤ 5 cm: no difference in 1-, 2- and 3-yr DFS |
| Li *et al* (2017)[117] | Retrospective cohort | LR *vs* LR+TACE | 459 control *vs* 295 treatment | LR + TACE improved postoperative recurrence and long-term survival. | Patients with HCC beyond Milan Criteria. |
| Ye *et al* (2017)[170] | Retrospective cohort | LR *vs* LR+TACE | 260 microvascular invasion (86 in LR +TACE) resection; 259 w/o microvascular invasion (72 in LR+TACE) arm | LR + TACE improved OS and DFS in patients with microvascular invasion but not in patients without microvascular invasion. | All patients had BCLC Stage A or B |
| Qi *et al* (2018)[171] | Retrospective cohort | LR *vs* LR+TACE | 200 patients with microvascular invasion (91 LR +TACE *vs* 109 LR only) | Similar 1-, 2- and 3-yr DFS between groups. Subgroup with tumor size > 5 cm had better DFS and OS with LR+TACE. | All patients had microvascular invasion and were BCLC A or B stage. |
| Liao *et al* (2017)[123] | Meta-analysis | LR *vs* LR+TACE | 8 RCTs and 12 retrospective studies, totaling 3191 patients (1193 treatment *vs* 1952 control). | Significantly higher RFS and OS benefit with postoperative adjuvant TACE compared to surgery alone | Good consistency in findings between RCTs and non-RCTs, however, chemotherapy regimens differed between centers/trials. |

LR: Liver resection; LR+TACE: Liver resection plus adjuvant transarterial chemoembolization; HCC: Hepatocellular carcinoma; DFS: Disease-free survival; OS: Overall survival; BCLC: Barcelona Clinic Liver Cancer; RCT: Randomized controlled trial; RFS: Recurrence-free survival.